Natco Pharma Gets Court Nod to Make, Export Semaglutide for Diabetes and Obesity Markets
New Delhi: Natco Pharma has secured regulatory clearance from the High Court to manufacture semaglutide and export the drug to select international markets, marking a significant regulatory milestone for the company's expansion in the diabetes and obesity treatment segment.
As per the court order, the company is authorized to commence production of semaglutide, a widely prescribed therapy for type 2 diabetes and weight management. The approval also permits exports to certain overseas markets, although the specific destination countries were not disclosed, according to a report by Scanx.
The development strengthens Natco Pharma’s manufacturing capabilities and enhances its positioning in the chronic disease portfolio, particularly in metabolic disorders.
With export permissions in place, the company is also positioned to explore growth opportunities beyond the domestic market, subject to regulatory approvals in the respective jurisdictions, as per Scanx.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.